Date,Symbol,Headline,Source11/11/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Healthcare Conference for 18-November-2020 10:00 AM ET",FCSTEV11/11/20,ZGNX-US,DJ Press Release: Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference,DJGM11/11/20,ZGNX-US,Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference,PMZ11/9/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update -2-,DJGM11/9/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results,DJGM11/9/20,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results,PMZ11/9/20,ZGNX-US,"Zogenix, Inc. to Host Earnings Call",NEWS_ACW10/29/20,ZGNX-US,DJ Press Release: Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9,DJGM10/29/20,ZGNX-US,Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9,PMZ10/26/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2020 Earnings Call for 9-November-2020 4:30 PM ET",FCSTEV10/26/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2020 Earnings Release for 9-November-2020 4:01 PM ET",FCSTEV10/26/20,ZGNX-US,DJ Press Release: Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10,DJGM10/26/20,ZGNX-US,Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10,PMZ10/16/20,ZGNX-US,Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome,PMZ10/16/20,ZGNX-US,DJ Press Release: Zogenix Receives Positive CHMP -2-,DJGM10/16/20,ZGNX-US,DJ Press Release: Zogenix Receives Positive CHMP Opinion for FINTEPLA(R) (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome,DJGM10/15/20,ZGNX-US,Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020,PMZ10/15/20,ZGNX-US,DJ Press Release: Zogenix Presents New Data for FINTEPLA(R) in Dravet Syndrome at CNS 2020,DJGM10/5/20,ZGNX-US,"Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027",PMZ10/5/20,ZGNX-US,"DJ Press Release: Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027",DJGM10/2/20,ZGNX-US,Zogenix Presents New Data  at the World Muscle Society Conference 2020,PMZ10/2/20,ZGNX-US,DJ Press Release: Zogenix Presents New Data at the World Muscle Society Conference 2020,DJGM9/23/20,ZGNX-US,"Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering",PMZ9/23/20,ZGNX-US,"DJ Press Release: Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering",DJGM9/22/20,ZGNX-US,"Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering ",PMZ9/22/20,ZGNX-US,"DJ Press Release: Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering",DJGM9/21/20,ZGNX-US,DJ Press Release: CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors,DJGM9/21/20,ZGNX-US,CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors,PMZ9/21/20,ZGNX-US,Zogenix Appoints Three Industry Leaders to Its Board of Directors,PMZ9/10/20,ZGNX-US,DJ Press Release: Zogenix Announces Positive -2-,DJGM9/10/20,ZGNX-US,DJ Press Release: Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of FINTEPLA(R) in Dravet Syndrome,DJGM9/10/20,ZGNX-US,Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of FINTEPLA® in Dravet Syndrome,PMZ8/5/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update -2-,DJGM8/5/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results,DJGM8/5/20,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results,PMZ7/29/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2020 Earnings Release for 5-August-2020 4:01 PM ET",FCSTEV7/29/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2020 Earnings Call for 5-August-2020 4:30 PM ET",FCSTEV7/29/20,ZGNX-US,Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5,PMZ6/26/20,ZGNX-US,DJ Press Release: FDA Approves FINTEPLA(R) -2-,DJGM6/26/20,ZGNX-US,DJ Press Release: FDA Approves FINTEPLA(R) (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome,DJGM6/25/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Fintepla FDA Approval Call for 26-June-2020 8:30 AM ET",FCSTEV6/25/20,ZGNX-US,FDA Approves FINTEPLA®  (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome,PRN6/12/20,ZGNX-US,Zogenix Introduces New Resources for Dravet Syndrome Siblings,PMZ6/12/20,ZGNX-US,DJ Press Release: Zogenix Introduces New Resources for Dravet Syndrome Siblings,DJGM5/8/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Bank of America Merrill Lynch Virtual Healthcare Conference for 13-May-2020 3:00 PM ET",FCSTEV5/6/20,ZGNX-US,Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference,PMZ5/5/20,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results,PMZ5/5/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results,DJGM5/5/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update -2-,DJGM4/28/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2020 Earnings Call for 5-May-2020 4:30 PM ET",FCSTEV4/28/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2020 Earnings Release for 5-May-2020 4:01 PM ET",FCSTEV4/28/20,ZGNX-US,Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5,PMZ4/20/20,ZGNX-US,"DJ Press Release: Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary",DJGM4/20/20,ZGNX-US,"Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary",PMZ4/20/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 29-May-2020 12:00 PM ET",FCSTEV4/15/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Business Update Call for 22-April-2020 1:00 PM ET",FCSTEV4/15/20,ZGNX-US,Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome,PMZ3/6/20,ZGNX-US,"Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares",PMZ3/6/20,ZGNX-US,"DJ Press Release: Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares",DJGM3/3/20,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ3/3/20,ZGNX-US,DJ Press Release: Zogenix Prices Public Offering of Common Stock,DJGM3/3/20,ZGNX-US,Zogenix Announces Proposed Public Offering of Common Stock,PMZ3/3/20,ZGNX-US,DJ Press Release: Zogenix Announces Proposed Public Offering of Common Stock,DJGM3/2/20,ZGNX-US,Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results,PMZ3/2/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update -2-,DJGM3/2/20,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results,DJGM2/27/20,ZGNX-US,DJ Press Release: Zogenix Announces FDA Extension of Review Period for FINTEPLA(R) in Dravet Syndrome,DJGM2/27/20,ZGNX-US,Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome,PMZ2/24/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2019 Earnings Release for 2-March-2020 4:01 PM ET",FCSTEV2/24/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2019 Earnings Call for 2-March-2020 4:30 PM ET",FCSTEV2/24/20,ZGNX-US,DJ Press Release: Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2,DJGM2/24/20,ZGNX-US,Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2,PMZ2/6/20,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules FINTEPLA Phase 3 Clinical Trial Results Call for 6-February-2020 4:30 PM ET",FCSTEV2/6/20,ZGNX-US,Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial  of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome,PMZ12/17/19,ZGNX-US,The Lancet Publishes Phase 3 Trial Results for Zogenix  Investigational Drug FINTEPLA® in Dravet Syndrome,PMZ12/17/19,ZGNX-US,DJ Press Release: The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA(R) in Dravet Syndrome,DJGM12/17/19,ZGNX-US,DJ Press Release: The Lancet Publishes Phase 3 Trial -2-,DJGM12/9/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting for 9-December-2019 12:00 PM ET",FCSTEV12/5/19,ZGNX-US,DJ Press Release: Zogenix to Host Investor Update Lunch on FINTEPLA(R) at the American Epilepsy Society 2019 Annual Meeting,DJGM12/5/19,ZGNX-US,Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting,PMZ12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 292 for 9-December-2019 8:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 203 for 8-December-2019 10:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 431 for 9-December-2019 8:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 419 for 7-December-2019 12:00 PM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 224 for 8-December-2019 10:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 430 for 9-December-2019 8:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 438 for 8-December-2019 10:00 AM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster No - 217 for 7-December-2019 12:00 PM ET",FCSTEV12/4/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting for 8-December-2019 8:00 AM ET",FCSTEV12/2/19,ZGNX-US,JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens ,PMZ12/2/19,ZGNX-US,DJ Press Release: JAMA Neurology Publishes Phase 3 -2-,DJGM12/2/19,ZGNX-US,DJ Press Release: JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA(R) in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens,DJGM12/2/19,ZGNX-US,DJ Press Release: Zogenix to Present New Data for Its Investigational Drug FINTEPLA(R) at the American Epilepsy Society Annual Meeting,DJGM12/2/19,ZGNX-US,Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting,PMZ11/27/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Piper Jaffray Healthcare Conference for 5-December-2019 10:00 AM ET",FCSTEV11/27/19,ZGNX-US,DJ Press Release: Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference,DJGM11/27/19,ZGNX-US,Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference,PMZ11/25/19,ZGNX-US,DJ Press Release: Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA(R) for the Treatment of Dravet Syndrome,DJGM11/25/19,ZGNX-US,Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome,PMZ11/21/19,ZGNX-US,"Shareholder Alert: Robbins LLP Reminds Investors Zogenix, Inc. (ZGNX) Sued for Misleading Shareholders",BW11/12/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Guggenheim Healthcare Talks, Idea Forum and Neuro Immunology Day for 18-November-2019 2:30 PM ET",FCSTEV11/12/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Health Care Conference for 19-November-2019 4:45 PM ET",FCSTEV11/12/19,ZGNX-US,DJ Press Release: Zogenix to Present at Two Investor Conferences in November,DJGM11/12/19,ZGNX-US,Zogenix to Present at Two Investor Conferences in November,PMZ11/7/19,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results,DJGM11/7/19,ZGNX-US,DJ Press Release: Zogenix Provides Corporate Update -2-,DJGM11/7/19,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results,PMZ10/31/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2019 Earnings Call for 7-November-2019 4:30 PM ET",FCSTEV10/31/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2019 Earnings Release for 7-November-2019 4:01 PM ET",FCSTEV10/31/19,ZGNX-US,DJ Press Release: Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7,DJGM10/31/19,ZGNX-US,Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7,PMZ10/25/19,ZGNX-US,DJ Press Release: Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA(R) in Dravet Syndrome,DJGM10/25/19,ZGNX-US,DJ Press Release: Zogenix Announces New Positive -2-,DJGM10/25/19,ZGNX-US,Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA®  in Dravet Syndrome,PMZ10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #36 for 25-October-2019 7:00 AM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster # 38 for 25-October-2019 7:00 AM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #62 for 25-October-2019 7:00 AM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster # 38 for 24-October-2019 4:00 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #62 for 24-October-2019 4:00 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #41 for 24-October-2019 12:45 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #44 for 24-October-2019 4:00 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #36 for 24-October-2019 4:00 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #41 for 24-October-2019 4:00 PM ET",FCSTEV10/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Child Neurology Society Meeting - Poster #44 for 25-October-2019 7:00 AM ET",FCSTEV10/21/19,ZGNX-US,DJ Press Release: Zogenix Announces Presentation of New Data for FINTEPLA(R) for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting,DJGM10/21/19,ZGNX-US,Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting,PMZ10/8/19,ZGNX-US,"Bragar Eagel & Squire is Investigating Certain Officers and Directors of CBL & Associates Properties, EQT Corporation, and Zogenix and Encourages Investors to Contact the Firm ",PMZ10/7/19,ZGNX-US,Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency,PMZ9/26/19,ZGNX-US,Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration,PMZ9/23/19,ZGNX-US,"ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm",PMZ9/18/19,ZGNX-US,"Bragar Eagel & Squire is Investigating Certain Officers and Directors of Orion Group Holdings, Zogenix, and Apyx and Encourages Investors to Contact the Firm",PMZ9/16/19,ZGNX-US,"ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ9/9/19,ZGNX-US,"Zogenix Completes Acquisition of Modis Therapeutics, Inc. ",PMZ9/4/19,ZGNX-US,"ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ8/26/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Acquisition of Modis Therapeutics, Inc by Zogenix, Inc Call for 26-August-2019 8:30 AM ET",FCSTEV8/26/19,ZGNX-US,"Zogenix Announces Acquisition of Modis Therapeutics, Inc.",PMZ8/6/19,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter 2019 Financial Results,PMZ7/30/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2019 Earnings Call for 6-August-2019 4:30 PM ET",FCSTEV7/30/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2019 Earnings Release for 6-August-2019 4:01 PM ET",FCSTEV7/30/19,ZGNX-US,Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6,PMZ7/8/19,ZGNX-US,Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome,PMZ6/27/19,ZGNX-US,Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA  ,PMZ6/7/19,ZGNX-US,"Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Actions",PMZ6/6/19,ZGNX-US,ZGNX and APYX DEADLINE ALERT: Hagens Berman Reminds APYX and ZGNX Investors of Lead Plaintiff Deadlines,PMZ6/6/19,ZGNX-US,"CLASS ACTION UPDATE for ZGNX, MWA, KSHB and SCOR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ6/5/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm",PMZ6/5/19,ZGNX-US,"ZGNX NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Investigation of Securities Claims Against Zogenix, Inc. Investors with Losses in Excess of $100K are Encouraged to Contact the Firm - ZGNX",BW6/5/19,ZGNX-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline - ZGNX",PMZ6/4/19,ZGNX-US,"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.",PMZ6/1/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses to Contact the Firm",PRN5/31/19,ZGNX-US,"CLASS ACTION UPDATES for BA, CRCM, ZGNX, INVVY: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders",PMZ5/29/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm ",PMZ5/23/19,ZGNX-US,ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Class Action of Upcoming Deadline,PMZ5/22/19,ZGNX-US,"CLASS ACTION UPDATE for CRCM, ZGNX, S and EQBK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ5/22/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm",PMZ5/21/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PMZ5/20/19,ZGNX-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline - ZGNX",PMZ5/17/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm",PMZ5/14/19,ZGNX-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline- ZGNX",PRN5/13/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PMZ5/13/19,ZGNX-US,SHAREHOLDER ALERT: MBT NTNX ZGNX INVVY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ5/10/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm",PMZ5/9/19,ZGNX-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline - ZGNX",PMZ5/8/19,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results,PMZ5/7/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Bank of America Merrill Lynch Health Care Conference for 14-May-2019 8:00 PM ET",FCSTEV5/7/19,ZGNX-US,Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference,PMZ5/7/19,ZGNX-US,"Lawsuit for Investors in Zogenix, Inc. (NASDAQ: ZGNX) shares announced by Shareholders Foundation",NEWS_ACW5/3/19,ZGNX-US,"SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of SCOR, MWA, and ZGNX of Upcoming Deadlines",PMZ5/3/19,ZGNX-US,"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.",BW5/2/19,ZGNX-US,"Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.",BW5/2/19,ZGNX-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline - ZGNX",PMZ5/2/19,ZGNX-US,"ZGNX CLASS ACTION ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. - ZGNX",PRN5/1/19,ZGNX-US,"ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Securities Class Action, Encourages Investors Who Suffered Losses of $50,000+ to Contact the Firm",PMZ5/1/19,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ5/1/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PMZ5/1/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2019 Earnings Call for 8-May-2019 4:30 PM ET",FCSTEV5/1/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2019 Earnings Release for 8-May-2019 4:01 PM ET",FCSTEV5/1/19,ZGNX-US,Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8,PMZ4/30/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Zogenix, Inc. to Contact the Firm",BW4/29/19,ZGNX-US,"ZGNX DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zogenix, Inc. - ZGNX",PMZ4/28/19,ZGNX-US,"INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines - BA, SCOR, MWA and ZGNX",PMZ4/26/19,ZGNX-US,"Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors",BW4/26/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm",PMZ4/25/19,ZGNX-US,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Investors (ZGNX)",BW4/25/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PMZ4/22/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PRN4/19/19,ZGNX-US,"ZGNX CLASS ACTION ALERT: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action - ZGNX",BW4/18/19,ZGNX-US,"IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW4/18/19,ZGNX-US,"Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX)",PMZ4/17/19,ZGNX-US,"Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)",PMZ4/17/19,ZGNX-US,"ZOGENIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Zogenix, Inc.",PMZ4/17/19,ZGNX-US,SHAREHOLDER ALERT: DPLO BV ZGNX MWA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ4/16/19,ZGNX-US,"ZGNX CLASS ACTION ALERT: Hagens Berman Alerts Zogenix (ZGNX) Investors to Securities Class Action, Encourages Investors to Contact the Firm",PRN4/16/19,ZGNX-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm",PMZ4/16/19,ZGNX-US,"EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. - ZGNX",BW4/15/19,ZGNX-US,"Hagens Berman Alerts Zogenix (ZGNX) Investors of the Firm's Investigation of Possible Securities Law Violations, Encourages Investors to Contact the Firm",PRN4/13/19,ZGNX-US,"Former California Deputy Attorney General and Special Counsel with Johnson Fistel Launches Investigation into Zogenix, Inc. (ZGNX)",PRN4/12/19,ZGNX-US,"Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX) and Encourages ZGNX Investors to Contact the Firm",PMZ4/12/19,ZGNX-US,"Pomerantz Law Firm Announces the Filing of a Class Action against  Zogenix, Inc. and Certain Officers - ZGNX",PMZ4/11/19,ZGNX-US,"INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW4/11/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 22-May-2019 12:00 PM ET",FCSTEV4/11/19,ZGNX-US,"Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)",BW4/10/19,ZGNX-US,"Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)",BW4/10/19,ZGNX-US,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zogenix, Inc. Investors",BW4/10/19,ZGNX-US,"Bragar Eagel & Squire, P.C. is Investigating Zogenix, Inc. (ZGNX) on Behalf of Stockholders and Encourages ZGNX Investors to Contact the Firm",PMZ4/10/19,ZGNX-US,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW4/10/19,ZGNX-US,Zogenix Investigated by Block & Leviton LLP For Violations of Federal Securities Laws,PMZ4/9/19,ZGNX-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zogenix, Inc. - ZGNX",PRN4/8/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules FINTEPLA NDA Update Call for 8-April-2019 4:30 PM ET",FCSTEV4/8/19,ZGNX-US,Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application,PMZ4/1/19,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ3/26/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules William Blair Late-Stage Therapeutics Conference for 4-April-2019 8:00 AM ET",FCSTEV3/26/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel CNS Day for 1-April-2019 3:35 PM ET",FCSTEV3/25/19,ZGNX-US,Zogenix to Present at Two Investor Conferences in April,PMZ3/19/19,ZGNX-US,Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan,PMZ3/1/19,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ2/28/19,ZGNX-US,Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results,PMZ2/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2018 Earnings Release for 28-February-2019 4:01 PM ET",FCSTEV2/21/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2018 Earnings Call for 28-February-2019 4:30 PM ET",FCSTEV2/21/19,ZGNX-US,Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28,PMZ2/20/19,ZGNX-US,Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference,PMZ2/6/19,ZGNX-US,Zogenix Submits New Drug Application to U.S. Food & Drug Administration  and Marketing Authorization Application to European Medicines Agency  for FINTEPLA® for the Treatment of Dravet Syndrome,PMZ2/1/19,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ1/31/19,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules SVB Leerink Partners Global Health Care Conference for 27-February-2019 9:00 AM ET",FCSTEV1/2/19,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ12/3/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ12/3/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting for 3-December-2018 1:00 PM ET",FCSTEV12/3/18,ZGNX-US,Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome,PMZ12/2/18,ZGNX-US,Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome,PMZ11/29/18,ZGNX-US,Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting,PMZ11/27/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Mizuho Global Investor Conference for 4-December-2018",FCSTEV11/27/18,ZGNX-US,Zogenix to Participate in the Global Mizuho Investor Conference 2018,PMZ11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster #3.463 for 3-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster # 2.230 for 2-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster # 2.424 for 2-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster #:2.454 for 2-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster # 2.406 for 2-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster #3.461 for 3-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster # 3.202 for 3-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster # 2.243 for 2-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting for 2-December-2018 9:00 AM ET",FCSTEV11/26/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Epilepsy Society Meeting - Poster #3.453 for 3-December-2018 1:00 PM ET",FCSTEV11/26/18,ZGNX-US,Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting,PMZ11/8/18,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter Financial Results,PMZ11/7/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Health Care Conference for 14-November-2018 8:45 AM ET",FCSTEV11/7/18,ZGNX-US,Zogenix to Present at Stifel 2018 Healthcare Conference,PMZ11/1/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2018 Earnings Call for 8-November-2018 4:30 PM ET",FCSTEV11/1/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2018 Earnings Release for 8-November-2018 After Market Hours ET",FCSTEV11/1/18,ZGNX-US,Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8,PMZ10/1/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ9/25/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners LLC Roundtable Series Rare Disease & Oncology Conference for 2-October-2018 10:30 AM ET",FCSTEV9/25/18,ZGNX-US,Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology,PMZ9/4/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ9/4/18,ZGNX-US,Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome,PMZ8/30/18,ZGNX-US,Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology,PMZ8/7/18,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ8/6/18,ZGNX-US,"Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock",PMZ8/6/18,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter Financial Results,PMZ8/1/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ8/1/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2018 Earnings Call for 6-August-2018 4:30 PM ET",FCSTEV8/1/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2018 Earnings Release for 6-August-2018 After Market Hours ET",FCSTEV8/1/18,ZGNX-US,Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6,PMZ7/12/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules ZX008 Pivotal Phase III Clinical Trial Results Call for 12-July-2018 8:30 AM ET",FCSTEV7/12/18,ZGNX-US,Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome,PMZ7/2/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ7/2/18,ZGNX-US,Zogenix Welcomes New Global Chief Commercial Officer,PMZ6/1/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ5/14/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Bank of America Merrill Lynch Health Care Conference for 17-May-2018 12:20 PM ET",FCSTEV5/14/18,ZGNX-US,Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference,PMZ5/9/18,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter Financial Results,PMZ5/4/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2018 Earnings Call for 9-May-2018 4:30 PM ET",FCSTEV5/4/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2018 Earnings Release for 9-May-2018 After Market Hours ET",FCSTEV5/4/18,ZGNX-US,Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9,PMZ5/1/18,ZGNX-US,Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),PMZ4/27/18,ZGNX-US,Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome,PMZ4/25/18,ZGNX-US,Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome,PMZ4/20/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Academy of Neurology Meeting for 21-April-2018",FCSTEV4/17/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 23-May-2018 11:00 AM ET",FCSTEV4/11/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners CNS Day for 18-April-2018 2:40 PM ET",FCSTEV4/11/18,ZGNX-US,Zogenix to Participate in LEERINK Partners CNS Day,PMZ3/6/18,ZGNX-US,Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results,PMZ3/6/18,ZGNX-US,"Zogenix, Inc. to Host Earnings Call",NEWS_ACW2/27/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2017 Earnings Call for 6-March-2018 4:30 PM ET",FCSTEV2/27/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2017 Earnings Release for 6-March-2018 After Market Hours ET",FCSTEV2/27/18,ZGNX-US,Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6,PMZ2/8/18,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules LEERINK Partners Global Healthcare Conference for 15-February-2018 9:00 AM ET",FCSTEV2/8/18,ZGNX-US,Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference,PMZ2/6/18,ZGNX-US,Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome,PMZ1/31/18,ZGNX-US,Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome,PMZ1/4/18,ZGNX-US,Counsyl Appoints Ann Rhoads to Board of Directors,BW12/4/17,ZGNX-US,Zogenix Announces New Positive Efficacy and Safety Data from  Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome,PMZ11/29/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Mizuho Americas Global Investor Conference for 5-December-2017",FCSTEV11/29/17,ZGNX-US,Zogenix Announces Initiation of Phase 3 Trial for  ZX008 in Lennox-Gastaut Syndrome,PMZ11/29/17,ZGNX-US,Zogenix to Participate in the Global Mizuho Investor Conference 2017,PMZ11/28/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Business Update Call for 4-December-2017 4:30 PM ET",FCSTEV11/28/17,ZGNX-US,"Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4",PMZ11/21/17,ZGNX-US,New Data from Zogenix's Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting,PMZ11/14/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Nicolaus Health Care Conference for 15-November-2017 8:45 AM ET",FCSTEV11/14/17,ZGNX-US,Zogenix to Present at Stifel 2017 Healthcare Conference,PMZ11/7/17,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results,PMZ11/7/17,ZGNX-US,"Zogenix, Inc. to Host Earnings Call",NEWS_ACW10/31/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2017 Earnings Release for 7-November-2017 After Market Hours ET",FCSTEV10/31/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2017 Earnings Call for 7-November-2017 4:30 PM ET",FCSTEV10/31/17,ZGNX-US,Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7,PMZ10/16/17,ZGNX-US,Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy,PMZ10/5/17,ZGNX-US,"Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares",PMZ10/3/17,ZGNX-US,Biotech Sector Notches Impressive Year-to-date Returns With Positive Outlook for Development of New Drugs and Therapies,PRN10/2/17,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ10/2/17,ZGNX-US,"Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock",PMZ9/29/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules ZX008 Phase 3 Trial Results Call for 29-September-2017 8:30 AM ET",FCSTEV9/29/17,ZGNX-US,Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome,PMZ8/8/17,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results,PMZ8/8/17,ZGNX-US,"Investor Network: Zogenix, Inc. to Host Earnings Call",NEWS_ACW8/1/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2017 Earnings Call for 8-August-2017 4:30 PM ET",FCSTEV8/1/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2017 Earnings Release for 8-August-2017 After Market Hours ET",FCSTEV8/1/17,ZGNX-US,Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8,PMZ6/22/17,ZGNX-US,Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome,PMZ6/14/17,ZGNX-US,"Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors",PMZ6/5/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Jefferies Global Health Care Conference for 7-June-2017 2:00 PM ET",FCSTEV5/31/17,ZGNX-US,Zogenix to Present at the Jefferies 2017 Global Healthcare Conference,PMZ5/22/17,ZGNX-US,Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry,PMZ5/4/17,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results,PMZ5/4/17,ZGNX-US,"Investor Network: Zogenix, Inc. to Host Earnings Call",NEWS_ACW5/1/17,ZGNX-US,Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome,NEWS_ACW4/27/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2017 Earnings Release for 4-May-2017 After Market Hours ET",FCSTEV4/27/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2017 Earnings Call for 4-May-2017 4:30 PM ET",FCSTEV4/27/17,ZGNX-US,Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome,PMZ4/27/17,ZGNX-US,Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4,PMZ4/20/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules American Academy of Neurology Meeting for 21-April-2017",FCSTEV4/14/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 23-May-2017",FCSTEV4/11/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Dravet Conference for 12-April-2017",FCSTEV3/15/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Oppenheimer Health Care Conference for 22-March-2017 2:10 PM ET",FCSTEV3/15/17,ZGNX-US,Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference,PMZ3/9/17,ZGNX-US,Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results,PMZ3/2/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2016 Earnings Release for 9-March-2017 After Market Hours ET",FCSTEV3/2/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2016 Earnings Call for 9-March-2017 4:30 PM ET",FCSTEV3/2/17,ZGNX-US,Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9,PMZ3/1/17,ZGNX-US,Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome,PMZ2/15/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules RBC Capital Markets Health Care Conference for 22-February-2017",FCSTEV2/15/17,ZGNX-US,Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference,PMZ2/13/17,ZGNX-US,Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome,PMZ2/8/17,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners Global Healthcare Conference for 15-February-2017 9:30 AM ET",FCSTEV2/8/17,ZGNX-US,Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference,PMZ1/30/17,ZGNX-US,Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome,PMZ1/5/17,ZGNX-US,Zogenix Announces CFO Transition,PMZ12/5/16,ZGNX-US,Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome,PMZ11/24/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Oppenheimer Life Sciences Summit for 29-November-2016",FCSTEV11/22/16,ZGNX-US,New Data on Zogenix's ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting,PMZ11/22/16,ZGNX-US,Zogenix to Participate in Oppenheimer Life Sciences Summit 2016,PMZ11/8/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Healthcare Conference for 15-November-2016 3:45 PM ET",FCSTEV11/8/16,ZGNX-US,Zogenix to Participate in Stifel 2016 Healthcare Conference,PMZ11/7/16,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results,PMZ10/31/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2016 Earnings Release for 7-November-2016 After Market Hours ET",FCSTEV10/31/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2016 Earnings Call for 7-November-2016 4:30 PM ET",FCSTEV10/31/16,ZGNX-US,Zogenix to Release Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 7,PMZ9/20/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Ladenburg Thalmann Health Care Conference for 27-September-2016 4:00 PM ET",FCSTEV9/20/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners Roundtable Series Rare Disease and Immuno-Oncology Conference for 28-September-2016 10:00 AM ET",FCSTEV9/20/16,ZGNX-US,Zogenix to Participate in Two Upcoming Investor Conferences,PMZ9/8/16,ZGNX-US,Zogenix to have Significant Presence at 12th European Congress on Epileptology,PMZ8/9/16,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results,PMZ8/2/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2016 Earnings Call for 9-August-2016 4:30 PM ET",FCSTEV8/2/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2016 Earnings Release for 9-August-2016 After Market Hours ET",FCSTEV8/2/16,ZGNX-US,Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9,PMZ6/21/16,ZGNX-US,"Zogenix Announces Agreement to Refinance Debt, Further Increasing Company's Expected 2017 Cash Balance",PMZ6/7/16,ZGNX-US,Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome,PMZ6/7/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 13-July-2016",FCSTEV5/31/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Jefferies Health Care Conference for 7-June-2016 9:30 AM ET",FCSTEV5/31/16,ZGNX-US,Zogenix to Participate in Jefferies 2016 Healthcare Conference,PMZ5/10/16,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results,PMZ5/5/16,ZGNX-US,Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome,PMZ5/3/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2016 Earnings Call for 10-May-2016 4:30 PM ET",FCSTEV5/3/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2016 Earnings Release for 10-May-2016 After Market Hours ET",FCSTEV5/3/16,ZGNX-US,Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10,PMZ4/21/16,ZGNX-US,New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress,PMZ3/10/16,ZGNX-US,Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results,PMZ3/4/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2015 Earnings Call for 10-March-2016 4:30 PM ET",FCSTEV3/4/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2015 Earnings Release for 10-March-2016 After Market Hours ET",FCSTEV3/4/16,ZGNX-US,Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10,PMZ2/3/16,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners Global Health Care Conference for 10-February-2016 10:40 AM ET",FCSTEV2/3/16,ZGNX-US,Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference,PMZ1/19/16,ZGNX-US,Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome,PMZ1/11/16,ZGNX-US,Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome,PMZ12/18/15,ZGNX-US,"Healthcare Sector Equities under the Scanner -- Zogenix, Amarin, SciClone Pharma, and PetMed Express",NEWS_ACW12/14/15,ZGNX-US,Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome,PMZ12/7/15,ZGNX-US,Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome,PMZ11/25/15,ZGNX-US,New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting,PMZ11/11/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Health Care Conference for 18-November-2015 11:00 AM ET",FCSTEV11/11/15,ZGNX-US,Zogenix to Participate in Stifel 2015 Healthcare Conference,PMZ11/9/15,ZGNX-US,Zogenix Provides Corporate Update and Reports Third Quarter 2015 Financial Results,PMZ11/2/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2015 Earnings Call for 9-November-2015 4:30 PM ET",FCSTTS11/2/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2015 Earnings Release for 9-November-2015 After Market Hours ET",FCSTTS11/2/15,ZGNX-US,Zogenix to Release Third Quarter 2015 Financial Results and Host Conference Call & Webcast on November 9,PMZ10/19/15,ZGNX-US,Zogenix Provides Regulatory Update for ZX008,PMZ10/5/15,ZGNX-US,"Tokalas appoints James B. Breitmeyer, M.D., Ph.D., President & CEO",PRN9/30/15,ZGNX-US,Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial,PMZ9/23/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners Rare Disease Roundtable Conference for 30-September-2015 9:40 AM ET",FCSTTS9/23/15,ZGNX-US,Zogenix to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable,PMZ9/3/15,ZGNX-US,Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference,PMZ8/10/15,ZGNX-US,Zogenix Provides Corporate Update and Reports Second Quarter 2015 Financial Results,PMZ8/10/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Wells Fargo Healthcare Conference for 10-September-2015 8:35 AM ET",FCSTEV8/5/15,ZGNX-US,"Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares",PMZ8/3/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2015 Earnings Release for 10-August-2015 After Market Hours ET",FCSTEV8/3/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2015 Earnings Call for 10-August-2015 4:30 PM ET",FCSTTS8/3/15,ZGNX-US,Zogenix to Release Second Quarter 2015 Financial Results and Host Conference Call & Webcast on August 10,PMZ7/30/15,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ7/28/15,ZGNX-US,"Zogenix Announces Proposed Public Offering of 3,800,000 Shares of Common Stock",PMZ7/21/15,ZGNX-US,"Leadership Appointments Bodes Well with Strategic Focus - Report on Zogenix, Inc.",PRN7/13/15,ZGNX-US,Biotech Briefing: FDA Events & Recent Clinical Trials Fuel Therapeutic Advancements That Continue to Drive the Pharma & Biotech Sectors,PRN7/7/15,ZGNX-US,"Zogenix to Host Key Opinion Leader Meeting Tuesday, July 14, in New York City",PMZ7/6/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Cantor Fitzgerald Healthcare Conference for 8-July-2015 1:30 PM ET",FCSTTS7/6/15,ZGNX-US,Zogenix Expands Senior Leadership Team to Further Drive Strategic Focus on CNS Disorders and Orphan Drug Development,PMZ7/6/15,ZGNX-US,Zogenix to Participate in Cantor Fitzgerald Healthcare Conference,PMZ7/1/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Cantor Fitzgerald Inaugural Health Care Conference for 8-July-2015 1:30 PM ET",FCSTEV6/18/15,ZGNX-US,Zogenix Announces Shareholders and Board of Directors Approve Reverse Stock Split,PMZ5/27/15,ZGNX-US,Zogenix Announces New Efficacy Data From a Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome,PMZ5/12/15,ZGNX-US,"Market Updates on Pharma Stocks - Zogenix, Valeant Pharma Intl., Sanofi, Novartis, and Ampio Pharma",PRN5/12/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 18-June-2015",FCSTTS5/11/15,ZGNX-US,Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results,PMZ5/4/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2015 Earnings Call for 11-May-2015 4:30 PM ET",FCSTTS5/4/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2015 Earnings Release for 11-May-2015 After Market Hours ET",FCSTTS5/4/15,ZGNX-US,Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11,PMZ4/27/15,ZGNX-US,Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline,PMZ4/24/15,ZGNX-US,Pernix Therapeutics Closes Acquisition of Zohydro ER Franchise,BW4/24/15,ZGNX-US,Zogenix Closes Sale of Zohydro(R) ER Business to Pernix,PMZ4/8/15,ZGNX-US,Post-Earnings Report - Zogenix,PRN3/26/15,ZGNX-US,Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study,PMZ3/10/15,ZGNX-US,"Pernix to Acquire Zohydro® ER Franchise from Zogenix, Inc.",BW3/10/15,ZGNX-US,Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million,PMZ3/10/15,ZGNX-US,Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results,PMZ3/10/15,ZGNX-US,"Technical Snapshot on Pharma Stocks -- Pfizer, Zogenix, Sanofi, Nektar Therapeutics, and IGI Laboratories",PRN3/2/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2014 Earnings Call for 10-March-2015 4:30 PM ET",FCSTTS3/2/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2014 Earnings Release for 10-March-2015 After Market Hours ET",FCSTTS3/2/15,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results,PMZ2/10/15,ZGNX-US,Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors,PMZ2/5/15,ZGNX-US,Zogenix to Participate in Leerink Global Healthcare Conference,PMZ2/3/15,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Global Health Care Conference for 11-February-2015 8:00 AM ET",FCSTEV2/2/15,ZGNX-US,"Pharma Equities Under the Scanner - Pfizer, Sanofi, Eli Lilly, AstraZeneca, and Zogenix",PRN1/30/15,ZGNX-US,Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER,PMZ1/12/15,ZGNX-US,Zogenix Provides Business Update,PMZ1/5/15,ZGNX-US,"Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.",PRN12/15/14,ZGNX-US,"Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis",PRN12/3/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Oppenheimer Healthcare Conference for 10-December-2014 10:55 AM ET",FCSTEV12/3/14,ZGNX-US,Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference,PMZ12/1/14,ZGNX-US,"Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER",PMZ11/12/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Healthcare Conference for 18-November-2014 11:30 AM ET",FCSTEV11/12/14,ZGNX-US,Zogenix to Participate in Stifel 2014 Healthcare Conference,PMZ11/6/14,ZGNX-US,Zogenix Reports Third Quarter 2014 Financial Results,PMZ11/4/14,ZGNX-US,"Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix",PRN10/31/14,ZGNX-US,Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products,PMZ10/30/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2014 Earnings Call for 6-November-2014 4:30 PM ET",FCSTEV10/30/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2014 Earnings Release for 6-November-2014 After Market Hours ET",FCSTEV10/30/14,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results,PMZ10/27/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Acquisition of Brabant Pharma by Zogenix, Inc Call for 27-October-2014 4:30 PM ET",FCSTEV10/27/14,ZGNX-US,Zogenix Acquires U.K.-Based Brabant Pharma,PMZ10/1/14,ZGNX-US,Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review,PMZ9/29/14,ZGNX-US,"Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD",PRN9/18/14,ZGNX-US,New Data Shows Zohydro(R) ER Reduced Pain and Improved Function in People With Chronic Pain,PMZ9/4/14,ZGNX-US,"Education, Patient-Focused Approach to Treating Chronic Pain Are Keys to Preventing Opioid Abuse, Say Experts, Patients",PMZ9/2/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Morgan Stanley Global Healthcare Conference for 10-September-2014 10:20 AM ET",FCSTEV9/2/14,ZGNX-US,Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014,PMZ9/2/14,ZGNX-US,Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief,PMZ8/21/14,ZGNX-US,"Pharma Stocks Review -- Eli Lilly, Zogenix, GlaxoSmithKline, Novo Nordisk, and Valeant Pharma Intl.",PRN8/5/14,ZGNX-US,Zogenix Reports Second Quarter 2014 Financial Results,PMZ8/1/14,ZGNX-US,"Zogenix Announces Departure of Chief Commercial Officer, Scott Shively",PMZ7/22/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2014 Earnings Call for 5-August-2014 4:30 PM ET",FCSTEV7/22/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2014 Earnings Release for 5-August-2014 After Market Hours ET",FCSTEV7/22/14,ZGNX-US,"Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis",PRN7/22/14,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results,PMZ7/17/14,ZGNX-US,"Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board",PMZ7/14/14,ZGNX-US,Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System,PMZ7/9/14,ZGNX-US,Zogenix Reports Positive Development on U.S. District Court Ruling,PMZ7/7/14,ZGNX-US,"Kosher Certifications, Biologic License Applications, Positive Study Results, Development Programs, and Product Acquisitions - Analyst Notes on Pfizer, Novartis, Sanofi, Zogenix and Impax",PRN7/2/14,ZGNX-US,Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER,PMZ6/23/14,ZGNX-US,"Technical Roundup on Health Care Sector Stocks -- Research on HCA Holdings, Community Health Systems, GlaxoSmithKline, and Zogenix",PRN6/16/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Wells Fargo Securities Healthcare Conference for 18-June-2014 2:25 PM ET",FCSTEV6/16/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules JMP Securities Healthcare Conference for 24-June-2014 10:00 AM ET",FCSTEV6/16/14,ZGNX-US,Zogenix to Present at Two Upcoming Conferences,PMZ6/2/14,ZGNX-US,Zogenix Officers to Report Withholding of Shares,PMZ5/30/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Jefferies Global Health Care Conference for 4-June-2014 2:30 PM ET",FCSTEV5/30/14,ZGNX-US,Zogenix to Present at Jefferies 2014 Global Healthcare Conference,PMZ5/30/14,ZGNX-US,"Equities Updates on Top Gainers -- Research on Comstock Resources, Zogenix, Mercadolibre, and Clovis Oncology",PRN5/19/14,ZGNX-US,Zogenix Closes Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International,PMZ5/8/14,ZGNX-US,Zogenix Reports First Quarter 2014 Financial Results,PMZ4/30/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2014 Earnings Release for 8-May-2014 After Market Hours ET",FCSTEV4/30/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2014 Earnings Call for 8-May-2014 4:30 PM ET",FCSTEV4/30/14,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results,PMZ4/24/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International by Zogenix Call for 24-April-2014 8:30 AM ET",FCSTEV4/24/14,ZGNX-US,Endo Acquires Rights to Sumavel® DosePro®,PRN4/24/14,ZGNX-US,Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International,PMZ4/23/14,ZGNX-US,"Zogenix Responds to Governor's Action Singling Out Zohydro™ ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures",PRN4/21/14,ZGNX-US,U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts ,NEWS_ACW4/15/14,ZGNX-US,Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Prevented Access to Zohydro™ ER,PRN4/12/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Annual General Meeting for 21-May-2014",FCSTEV4/11/14,ZGNX-US,Let's Get the Facts Straight About Zohydro™ ER--and the Important Patient Need It Fills,PRN4/8/14,ZGNX-US,Zogenix Update on Legal Action,PRN4/7/14,ZGNX-US,Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro™ ER,PRN4/2/14,ZGNX-US,Zogenix Statement: Let's Get the Facts Straight About Zohydro ER,PRN4/2/14,ZGNX-US,Zogenix Reports Granting of Inducement Awards,PMZ3/26/14,ZGNX-US,Zogenix Appoints James Breitmeyer to Its Board of Directors,PMZ3/12/14,ZGNX-US,"Five Star Equities Issues New Research Reports on OXGN, SNMX, SSH and ZGNX",NEWS_ACW3/5/14,ZGNX-US,Zogenix Reports Granting of Inducement Awards,PMZ2/27/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2013 Earnings Call for 5-March-2014 4:30 PM ET",FCSTTS2/27/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2013 Earnings Release for 5-March-2014 After Market Hours ET",FCSTTS2/27/14,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results,PMZ2/13/14,ZGNX-US,"Data From Zohydro(TM) ER (hydrocodone bitartrate) Phase 3 Clinical Trial Published in Pain Medicine Demonstrates Its Benefit as a Therapeutic Option for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment and for Which Alternative Treatment Options Are Inadequate",PMZ2/12/14,ZGNX-US,Zogenix Establishes External Safe-Use Board,PMZ2/11/14,ZGNX-US,Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans,PMZ2/11/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Partners Healthcare Conference for 11-February-2014 8:00 AM ET",FCSTTS2/4/14,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Swann Global Healthcare Conference for 12-February-2014 2:40 PM ET",FCSTTS2/4/14,ZGNX-US,Zogenix to Present at Leerink Swann 2014 Global Healthcare Conference,PMZ2/4/14,ZGNX-US,Zogenix Reports Granting of Inducement Awards,PMZ1/16/14,ZGNX-US,"Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix",PRN1/13/14,ZGNX-US,Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales,PMZ1/9/14,ZGNX-US,"Zogenix and Mallinckrodt Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective January 31, 2014",PMZ1/9/14,ZGNX-US,Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement,BW1/8/14,ZGNX-US,"Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix",PRN1/7/14,ZGNX-US,Zogenix Reports Granting of Inducement Awards,PMZ12/17/13,ZGNX-US,Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team,PMZ12/11/13,ZGNX-US,Zogenix Reports Granting of Inducement Awards,PMZ12/10/13,ZGNX-US,"Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix",PRN12/10/13,ZGNX-US,Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System,PMZ12/4/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Oppenheimer Health Care Conference for 11-December-2013 8:55 AM ET",FCSTEV12/4/13,ZGNX-US,Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference,PMZ12/3/13,ZGNX-US,Zogenix and Battelle Expand DosePro Technology Business Agreement,PMZ11/19/13,ZGNX-US,"Healthcare Sector Announced Reforms, Financial Results, Public Offerings, Top Rankings and Positive Data - Research Report on Kindred, Zogenix, Sangamo, PhotoMedex and Supernus Pharmaceuticals",PRN11/14/13,ZGNX-US,"Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.",PRN11/12/13,ZGNX-US,"Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters",PMZ11/5/13,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ11/4/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2013 Earnings Release for 4-November-2013",FCSTEV11/4/13,ZGNX-US,"VELT, LNCO, CSIQ and ZGNX added to NASDAQ Active Stock Watch List at GSR",NEWS_ACW11/4/13,ZGNX-US,Altus Formulation Signs Agreement With Zogenix for Development of Abuse Deterrent Formulations of Zohydro(TM) ER,PMZ11/4/13,ZGNX-US,"Presentation, Quarterly Reports, and FDA Approval - Research Report on Merck, United Therapeutics, Endo, Isis Pharmaceuticals, and Zogenix",PRN11/4/13,ZGNX-US,Zogenix Announces Proposed Public Offering of Common Stock,PMZ11/4/13,ZGNX-US,Zogenix Reports Third Quarter 2013 Financial Results,PMZ11/1/13,ZGNX-US,Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER With Altus Formulation,PMZ10/28/13,ZGNX-US,"SNTA, DNDN, ZGNX and NVGN added to NASDAQ Active Stock Watch List at EPR",NEWS_ACW10/25/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Zohydro ER FDA Approval Call for 28-October-2013 8:30 AM ET",FCSTEV10/25/13,ZGNX-US,Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules,PMZ10/25/13,ZGNX-US,"Pre-Market Analysis: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.",PRN10/7/13,ZGNX-US,"Changes in Senior Management, Grants of Orphan Drug Designations, and Updates on Pipeline Development and NDA - Research Report on Vivus, Omeros, Delcath Systems, Achillion, and Zogenix",PRN10/4/13,ZGNX-US,"Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.",PRN10/1/13,ZGNX-US,Zogenix Provides Update on Zohydro(TM) ER NDA,PMZ8/29/13,ZGNX-US,"Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.",PRN8/8/13,ZGNX-US,Zogenix Reports Second Quarter 2013 Financial Results,PMZ8/5/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2013 Earnings Release for 8-August-2013 After Market Hours ET",FCSTEV8/5/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2013 Earnings Call for 8-August-2013 4:30 PM ET",FCSTEV8/5/13,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Second Quarter 2013 Financial Results,PMZ8/1/13,ZGNX-US,Zogenix Begins Promotion of Migranal(R) Nasal Spray,PMZ6/27/13,ZGNX-US,Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray,PMZ6/25/13,ZGNX-US,Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month,PMZ6/5/13,ZGNX-US,Zogenix Announces Initiatives to Reach Key Business Milestones,PMZ5/20/13,ZGNX-US,"Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics",PMZ5/9/13,ZGNX-US,Zogenix Reports First Quarter 2013 Financial Results,PMZ5/7/13,ZGNX-US,The Global Needle-free Delivery Technology Market Will Reach $2.4 Billion in 2017 Predicts New Visiongain Report,PRNE5/3/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2013 Earnings Call for 9-May-2013 4:30 PM ET",FCSTEV5/3/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2013 Earnings Release for 9-May-2013 After Market Hours ET",FCSTEV5/3/13,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results,PMZ5/2/13,ZGNX-US,Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial,PMZ4/10/13,ZGNX-US,"Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma",PRN4/4/13,ZGNX-US,North American Injectable Drug Delivery Market worth $16.6 Billion by 2017,PRN3/27/13,ZGNX-US,Zogenix and Battelle Extend DosePro Co-Marketing Partnership,PMZ3/18/13,ZGNX-US,"Biotech Industry Looks to Benefit From FDA's New ""Breakthrough"" Designation",INW3/18/13,ZGNX-US,"Free Research Reports on KKD, STEC, VHC and ZGNX Issued by the Bedford Report",INW3/15/13,ZGNX-US,"Microcap Stocks To Watch - DAKP, ZGNX",NEWS_ACW3/15/13,ZGNX-US,Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results,PMZ3/7/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2012 Earnings Call for 15-March-2013 8:30 AM ET",FCSTEV3/7/13,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2012 Earnings Release for 15-March-2013 Before Market Open ET",FCSTEV3/7/13,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results,PMZ3/4/13,ZGNX-US,"R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer, Zogenix, Cubist, Merck and Questcor",PRN3/1/13,ZGNX-US,"Today's Technical View on Unitedhealth Group, Aetna, AstraZeneca, Oncothyreon, and Zogenix",PRN2/28/13,ZGNX-US,"Free Research Reports on ZGNX, MAKO, UNXL and MERU Issued by the Bedford Report",INW2/27/13,ZGNX-US,"Stocks on the Move - COPI, ZGNX, UNXL",NEWS_ACW2/26/13,ZGNX-US,Zogenix Provides Update on Zohydro(TM) ER Regulatory Review,PMZ2/7/13,ZGNX-US,"The Real Story Behind ZGNX, GERN, FTR and CBMX",INW1/7/13,ZGNX-US,"The Real Story Behind STSI, IMSC, CBIS and ZGNX ",INW1/7/13,ZGNX-US,Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales,PMZ1/3/13,ZGNX-US,DURECT Announces Positive Results from Relday™ Phase 1 Clinical Trial,PRN1/3/13,ZGNX-US,Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial,PMZ12/19/12,ZGNX-US,"Our Pros Knew MHR, ZGNX, OCLR and GDP Would Be Top Gainers on Tuesday ",INW12/18/12,ZGNX-US,"The Reason It Trades, What's Moving EJ, ZGNX, ALU and SD ",INW12/17/12,ZGNX-US,"Perfect Trade Setups, How to Play MDBX, STSI, ZGNX and AMRN ",INW12/14/12,ZGNX-US,"The Real Story Behind PCLN, SFMI, ZGNX and FTR ",INW12/12/12,ZGNX-US,"Stocks Traders Are Watching Closely: (NASDAQ: CTEL), (NASDAQ: ZGNX)",NEWS_ACW12/11/12,ZGNX-US,"The Real Story Behind ZGNX, GERN, FTR and CBMX ",INW12/11/12,ZGNX-US,"Free Research Reports on CLDX, DMND, PLXS and ZGNX Issued by the Bedford Report ",INW12/7/12,ZGNX-US,Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain,PMZ12/7/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Business Update Call for 7-December-2012 6:30 PM ET",FCSTEV12/7/12,ZGNX-US,Trading of Zogenix Common Stock Halted,PMZ11/26/12,ZGNX-US,Zogenix Appoints New Chief Commercial Officer,PMZ11/15/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Piper Jaffray Healthcare Conference for 28-November-2012 1:00 PM ET",FCSTEV11/15/12,ZGNX-US,Zogenix to Present at the 24th Annual Piper Jaffray Healthcare Conference,PMZ11/13/12,ZGNX-US,Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection,PMZ11/12/12,ZGNX-US,Semi-Annual Changes to the NASDAQ Biotechnology Index,PMZ11/8/12,ZGNX-US,Zogenix Reports Third Quarter 2012 Financial Results,PMZ11/8/12,ZGNX-US,Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain,PMZ10/25/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2012 Earnings Call for 8-November-2012 4:30 PM ET",FCSTEV10/25/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2012 Earnings Release for 8-November-2012 After Market Hours ET",FCSTEV10/25/12,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results,PMZ10/23/12,ZGNX-US,Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology,PMZ10/1/12,ZGNX-US,GreeneStone Muskoka Once Again Featured on Intervention Canada,BW9/27/12,ZGNX-US,Zogenix Announces Availability of New Resources for Migraine Sufferers at www.SUMAVELDosePro.com to Support National Pain Awareness Month,PMZ8/30/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Stifel Nicolaus Healthcare Conference for 6-September-2012 10:55 AM ET",FCSTEV8/30/12,ZGNX-US,Zogenix to Present at Stifel Nicolaus 2012 Healthcare Conference,PMZ8/9/12,ZGNX-US,Aradigm Announces Second Quarter 2012 Financial Results,BW8/8/12,ZGNX-US,Zogenix Reports Second Quarter 2012 Financial Results,PMZ8/1/12,ZGNX-US,Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank,PMZ7/31/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2012 Earnings Release for 8-August-2012 After Market Hours ET",FCSTEV7/31/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2012 Earnings Call for 8-August-2012 4:30 PM ET",FCSTEV7/31/12,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results,PMZ7/30/12,ZGNX-US,"Zogenix and Battelle Launch ""Less is More"" DosePro(R) Marketing Campaign",PMZ7/24/12,ZGNX-US,Zogenix Prices Public Offering of Common Stock and Warrants to Purchase Common Stock,PMZ7/23/12,ZGNX-US,Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock,PMZ7/16/12,ZGNX-US,Zogenix Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of Zohydro ER(TM) New Drug Application (NDA) for Treatment of Chronic Pain,PMZ7/12/12,ZGNX-US,Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia,PMZ6/7/12,ZGNX-US,"Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)",PMZ6/7/12,ZGNX-US,Mallinckrodt and Zogenix Announce Exclusive Co-Promotion Arrangement on SUMAVEL® DosePro®,BW5/30/12,ZGNX-US,Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM),PMZ5/14/12,ZGNX-US,Zogenix Reports First Quarter 2012 Financial Results,PMZ5/3/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2012 Earnings Call for 14-May-2012 4:30 PM ET",FCSTEV5/3/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2012 Earnings Release for 14-May-2012 After Market Hours ET",FCSTEV5/3/12,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results,PMZ5/2/12,ZGNX-US,Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain,PRN3/29/12,ZGNX-US,Zogenix and Battelle Ink Marketing Agreement for DosePro(R) Drug Delivery Technology,PMZ3/8/12,ZGNX-US,Zogenix Reports Fourth Quarter and Full Year 2011 Financial Results,PMZ2/27/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2011 Earnings Call for 8-March-2012 4:30 PM ET",FCSTEV2/27/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2011 Earnings Release for 8-March-2012 After Market Hours ET",FCSTEV2/27/12,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2011 Financial Results,PMZ2/10/12,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Swann Global Health Care Conference for 16-February-2012 2:00 PM ET",FCSTEV2/10/12,ZGNX-US,Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference,PMZ1/25/12,ZGNX-US,Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology,PMZ12/21/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Business Update Call for 21-December-2011 9:00 AM ET",FCSTEV12/21/11,ZGNX-US,Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL(R) DosePro(R),PMZ12/21/11,ZGNX-US,"Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective March 31, 2012",PMZ12/20/11,ZGNX-US,Zogenix Completes Zohydro(TM) Pre-NDA Meetings With FDA,PMZ11/21/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Piper Jaffray Health Care Conference for 29-November-2011 9:00 AM ET",FCSTEV11/21/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Swann Management Access Day Conference for 22-November-2011",FCSTEV11/21/11,ZGNX-US,Zogenix to Present at Two Upcoming Conferences,PMZ11/10/11,ZGNX-US,Zogenix Reports Third Quarter 2011 Financial Results,PMZ11/6/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2011 Earnings Call for 10-November-2011 4:30 PM ET",FCSTEV11/4/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q3 2011 Earnings Release for 10-November-2011 After Market Hours ET",FCSTEV11/4/11,ZGNX-US,Zogenix Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results,PMZ10/12/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Investor Meeting for 13-October-2011 7:30 AM ET",FCSTEV10/12/11,ZGNX-US,"Zogenix to Host Investor Meeting on October 13, 2011",PMZ9/30/11,ZGNX-US,Zogenix Achieves Zohydro(TM) Long-Term Safety Database for NDA,PMZ9/19/11,ZGNX-US,Zogenix to Present at UBS 2011 Global Life Sciences Conference,PMZ9/19/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules UBS Global Life Sciences Conference for 21-September-2011 7:30 AM ET",FCSTEV9/16/11,ZGNX-US,Zogenix Prices Public Offering of Common Stock,PMZ8/24/11,ZGNX-US,Zogenix Files Registration Statement for Proposed Follow-On Offering,PMZ8/17/11,ZGNX-US,Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint,PMZ8/17/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Zohydro Phase 3 Study Results Call for 17-August-2011 8:30 AM ET",FCSTEV8/16/11,ZGNX-US,Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain,PMZ8/10/11,ZGNX-US,Zogenix Reports Second Quarter 2011 Financial Results,PMZ8/4/11,ZGNX-US,Zogenix Announces Publication of SUMAVEL(R) DosePro(R) Phase 4 Clinical Data,PMZ8/2/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2011 Earnings Call for 10-August-2011 4:30 PM ET",FCSTEV8/2/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q2 2011 Earnings Release for 10-August-2011 After Market Hours ET",FCSTEV8/2/11,ZGNX-US,Zogenix Announces 2011 Second Quarter Conference Call and Webcast,PMZ7/18/11,ZGNX-US,Zogenix Closes $30 Million Royalty Financing With Cowen Healthcare Royalty Partners II,PMZ7/12/11,ZGNX-US,Zogenix and DURECT Announce Development and License Agreement for Antipsychotic Product Candidate,PMZ6/30/11,ZGNX-US,Zogenix Enters $30 Million Royalty Financing Agreement With Cowen Healthcare Royalty Partners II,PMZ6/13/11,ZGNX-US,Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference,PMZ6/6/11,ZGNX-US,Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month,PRN5/31/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Wells Fargo Securities Healthcare Conference for 22-June-2011 1:00 PM ET",FCSTEV5/27/11,ZGNX-US,Zogenix to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June,PMZ5/25/11,ZGNX-US,Zogenix Stockholders Elect Mark Wiggins to Board of Directors,PMZ5/18/11,ZGNX-US,Zogenix Highlights DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference,PMZ5/16/11,ZGNX-US,Zogenix Reports First Quarter 2011 Financial Results,PMZ5/11/11,ZGNX-US,Zogenix to Highlight DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference,PMZ5/4/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2011 Earnings Release for 16-May-2011 After Market Hours ET",FCSTEV5/4/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q1 2011 Earnings Call for 16-May-2011 4:30 PM ET",FCSTEV5/4/11,ZGNX-US,Zogenix to Hold Conference Call to Discuss First Quarter 2011 Financial Results,PMZ4/13/11,ZGNX-US,Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks,PMZ4/12/11,ZGNX-US,Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program,PMZ3/16/11,ZGNX-US,Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years,PMZ3/3/11,ZGNX-US,Zogenix Reports Fourth Quarter and Full Year 2010 Financial Results,PMZ3/1/11,ZGNX-US,Zogenix to Present SUMAVEL(R) DosePro(TM) Phase 4 Results at American Academy of Neurology,PMZ2/16/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2010 Earnings Release for 3-March-2011 After Market Hours ET",FCSTEV2/16/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Q4 2010 Earnings Call for 3-March-2011 4:30 PM ET",FCSTEV2/16/11,ZGNX-US,Zogenix to Hold Conference Call to Discuss Fourth Quarter and Full Year 2010 Financial Results,PMZ2/10/11,ZGNX-US,Zogenix Announces Completion of Enrollment in ZX002 Phase 3 Efficacy Study,PMZ2/9/11,ZGNX-US,"Zogenix, Inc.(ZGNX-US) Schedules Leerink Swann Hot Topics in Therapeutics Roundtable Conference for 17-February-2011 10:25 AM ET",FCSTEV2/9/11,ZGNX-US,Zogenix Receives 2011 Drug Delivery Partnerships Innovation Award for SUMAVEL(R) DosePro(TM),PMZ2/8/11,ZGNX-US,Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference,PMZ1/11/11,ZGNX-US,SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom,BW1/6/11,ZGNX-US,Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom,PMZ12/23/10,ZGNX-US,Zogenix Announces Partial Exercise of Over-Allotment Option for Initial Public Offering,PMZ12/13/10,ZGNX-US,Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM),PMZ12/7/10,ZGNX-US,SUMAVEL DosePro is Granted First European Approval,BW12/2/10,ZGNX-US,Zogenix and Desitin Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM),PMZ11/30/10,ZGNX-US,Zogenix Announces Completion of Enrollment in ZX002 Phase 3 12-Month Safety Study,PMZ11/22/10,ZGNX-US,Zogenix Announces Pricing of Initial Public Offering,PMZ9/7/10,ZGNX-US,Zogenix Files Registration Statement for Proposed Initial Public Offering,PRN7/13/10,ZGNX-US,Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital,PRN6/7/10,ZGNX-US,New Survey Reveals Critical Demand for Fast Migraine Relief,PRN3/17/10,ZGNX-US,Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone,PRN3/1/10,ZGNX-US,Zogenix Appoints New Chief Financial Officer,PRN1/13/10,ZGNX-US,SUMAVEL(TM) DosePro(TM) Available in the United States to Treat Acute Migraine and Cluster Headaches,PRN